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We have previously studied purified human myeloperoxidase-hydrogen peroxide-halide ion systems as 
models of possible singlet oxygen production by granulocytes. While myeloperoxidase could efficiently 
produce singlet oxygen, the yield of singlet oxygen at a physiological pH with Cl- was very small due to 
enzyme inactivation. In that Bolscher et al. [(1984) B&him. Biophys. Acta 784, 189-1911 observed that 
micromolar concentrations of ascorbic acid prevented inactivation of myeloperoxidase and increased the 
production of hypochlorous acid, we examined whether ascorbic acid would augment singlet oxygen pro- 
duction by the myeloperoxidase-hydrogen peroxide-halide ion systems. Ascorbic acid, however, fails to 
increase the singlet oxygen yield, suggesting that it does not augment singlet oxygen production in the intact 
granulocyte by a myeloperoxidase-dependent mechanism. 
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1. INTRODUCTION 
The biochemical oxidizing system consisting of 
myeloperoxidase, HZOZ and Cl- has been exten- 
sively studied as a model for the production of 
microbicidal and cytotoxic oxidant species by the 
human neutrophil [1,2]. While recent reports have 
emphasized the importance of HOC1 as a major 
mediator of this system [3--X?], whether another 
highly reactive species, singlet oxygen (‘02) is also 
produced in significant quantities has been much 
debated [7-151. In a recent study, we detected the 
characteristic 1268 nm ‘02 emission band in the 
myeloperoxidase-H202-halide systems and quan- 
titated the yield of ‘02 under a variety of condi- 
tions [16]. At acid pH, the production of ‘02 was 
stoichiometric with Br- and modestly efficient 
with Cl-, but at the more alkaline pH 
characteristic of the phagocytic vacuole, the pro- 
duction of ‘02 was very small 116-181. Enzyme in- 
activation was a major factor limiting the yield of 
‘OZ. The recent study of Bolscher et al. [I91 caused 
us to question the validity of the purified 
myelop~roxidase model. They demonstrated that 
the presence of micromolar concentrations of 
ascorbic acid protected the myeloperoxidase from 
inactivation. This raised the optimal pH for HOC1 
formation and produced a 3-fold increase in the 
HOC1 yield 1191. Since the concentration of ascor- 
bic acid in the human granulocyte is 150 gM 
[20,21], we undertook a study of the effect of 
ascorbic acid on the ‘02 yield of the 
myeloperoxidase-H202-halide systems. 
2. MATERIALS AND METHODS 
Details of the construction of the infrared 
chemiiuminescence spectrometer, method of quan- 
titation of ‘02 production using the Hz02 + HOC1 
reaction, purification of human myeloperoxidase 
and source of the reagents used have been reported 
previously [l&22,23]. The sample of myeloperox- 
idase used for this study had an &O/A280 = 0.7 
and an activity of 98 units/mg defined using 
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4-aminoantipyrine as a hydrogen donor [24]. 
Ascorbic acid was obtained from Sigma (St. Louis, 
MO). 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the effect of the addition of various 
amounts of ascorbic acid to the myeloperoxidase- 
HzOz-halide systems under conditions where the 
yield of ‘02 was low due to enzyme inactivation 
[ 161. No significant increase in ‘02 production was 
observed at any concentration. High concentra- 
tions of ascorbic acid decreased the yield of ‘02. 
Fig.2 demonstrates the effect of ascorbic acid on 
the kinetics of ‘02 production at p2H 4 with Cl-. 
Here the reaction rate is slow, but enzyme inactiva- 
tion is less important. Increasing concentrations of 
ascorbic acid caused a progressive delay in the 
onset of the chemiluminescence. 
We have previously used these highly purified 
myeloperoxidase systems as models of possible ‘02 
production by the intact granulocyte [16]. We 
reasoned that the purified myeloperoxidase system 
would set an upper limit to any ‘02 production by 
granulocytes via a myeloperoxidase-dependent 
mechanism, since the large concentration of 
biomolecules present in the granulocyte would 
compete with the Hz02 for any HOC1 produced, 
thus decreasing the amount of ‘02 formed 
[3,4,16,25]. An alternative hypothesis that we did 
Fig.1. Effect of ascorbic acid on the yield of singlet 
oxygen in the myeloperoxidase-HzOz-halide systems. 
(0) p2H 6, 100 mM sodium phosphate, 200 nM 
myeloperoxidase, 1 mM HzOZ, 100 mM NaCl, 
deuterium oxide solvent; (0) p2H 7, 100 mM sodium 
phosphate, 270 nM myeloperoxidase, 1 mM H202, 
100 mM NaBr, deuterium oxide solvent. 
300 
Fig.2. Effect of ascorbic acid on the kinetics of singlet 
0 60 120 
Time (s) 
oxygen production in the myeloperoxidase-H202-C1- 
system. Conditions: p2H 4, 100 mM sodium acetate, 
130 nM myeloperoxidase, 100 mM NaCI, deuterium 
oxide solvent. (A) No ascorbic acid; (B) 300 PM ascorbic 
acid; (C) 1 mM ascorbic acid. 
not consider was that the presence of ascorbic acid 
or other reducing substances would protect the 
myeloperoxidase from inactivation and increase 
the ‘02 yield. The data presented here demonstrate 
that this is not the case. Consistent with this study 
is the fact that we were unable to detect any 
1268 nm emission from human granulocytes 
stimulated with phorbol myristate acetate in 
Cl--containing buffers [26]. Unfortunately, in ex- 
periments with intact granulocytes, the anticipated 
luminescence is near the limit of sensitivity of the 
current spectrometer, so that small, but significant 
amounts of ‘02 may go undetected. 
Our myeloperoxidase system differs in an im- 
portant way from that described by Bolscher et al. 
[19]. The monochlorodimedone in their system 
prevented the accumulation of significant concen- 
trations of HOCl. In our Cl- system, moderate 
concentrations of HOC1 are required for the for- 
mation of ‘02, since the Hz02 + HOC1 reaction is 
relatively slow. Under these conditions HOC1 may 
irreversibly inactivate myeloperoxidase. Naskalski 
[27] has shown that 3 molecules of HOC1 are suffi- 
cient to destroy the heme group in myeloperox- 
idase and that this process cannot be reversed by 
ascorbic acid. This contrasts with the study of 
Bolscher et al. [19] where the major mechanism of 
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inactivation appeared to be the reversible forma- 
tion of Compound II. In our study, the most likely 
explanation for the decreased ‘02 yield caused by 
ascorbic acid is a direct reaction between HOC1 
and ascorbic acid. The kinetic data presented in 
fig.2 support this, since all of the ascorbic acid 
must be oxidized before any ‘02 is produced. The 
reaction of HOC1 with ascorbic acid may be fast 
enough to prevent the formation of ‘02, but not 
fast enough to prevent the inactivation of 
myeloperoxidase. Ascorbic acid is a well known 
quencher of ‘02, but in this study, the concentra- 
tions of ascorbic acid were too low to cause signifi- 
cant quenching. A concentration of 7 mM is re- 
quired to cause 50% quenching in deuterium oxide 
buffers [28]. 
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